Buyback Announcements and News

2/21/2025

Charles River Laboratories discloses CEO/COO share purchases - 8K ($163.02, 0.00)

  • On 20-Feb-25, James C. Foster, Chair, President and CEO purchased 6,075 shares of the company's common stock at an average price of $165.01 for an aggregate purchase price of ~$1M in open market transactions.
  • Birgit Girshick, Corporate EVP and COO of the company purchased 1,514 shares of the company's common stock at an average price of $164.63 for an aggregate purchase price of ~$250,000 in open market transactions.
  • Both Foster and Girshick indicated that they engaged in these transactions in recognition of the confidence they have in the strategic direction and long-term growth prospects of the company.
  • Foster and Girshick also terminated Rule 10b5-1 trading plans dated 26-Feb-24 and 22-Nov-23, respectively; Foster sold 25K of the 129.7K shares allotted while Girshick did not sell any of the 22.4K shares allotted in her plan.
  • Streetaccount notes Foster held a stake of ~245K shares and Girshick ~54K shares as of 31-Jan-25 Form 4 Filing

2/21/2025

Insider transaction: Solid Biosciences holder Perceptive Advisors discloses purchase of 5M shares - Form 4 ($5.78, 0.00)

  • Perceptive Advisors beneficially owns ~11.9M shares (indirect) of common stock following the transaction.
  • StreetAccount notes that the shares are held by funds managed by Joseph Edelman.

2/21/2025

StealthGas reports Q4 EPS $0.44 ex-items vs FactSet $0.29 [1 est]; increases share buyback ($5.55, 0.00)

  • Reports Q4:
    • Revenue $43.5M vs FactSet $39.6M [1 est]
    • Adjusted EBITDA $23.4M vs FactSet $19.8M [1 est]
    • Fleet utilization 96.2% vs year-ago 98.3%
  • As of February 2025, the company has total contracted revenues of ~$200M
  • As of February 2025, the company has circa 70% of fleet days secured under period contracts and contracted revenues of ~$107M for the remainder of the year
  • Share Repurchase Program Increase
    • The company authorized a $5M increase to the existing $25M common stock repurchase program for a total aggregate amount of $30M
    • As of the date hereof, the company has repurchased an aggregate of ~$19.4M.
  • Management comments:
    • It is with great pride that we announce today for the third consecutive year record annual profits. After a successful Q4 we concluded 2024 reporting net income of $70M for the year, a 35% increase, far outpacing the underlying market improvement for our vessels. We are delivering on our strategic priorities, modernizing the fleet, securing revenues and de-risking the business, aiming to bring strong value to StealthGas shareholders. We can now say we are net debt free, after having further reduced our debt in the current quarter. We are close to completing our deleverage that will bring a long term advantage to the fleet and the company is in a solid footing. As successful as we have been we are established in the shipping markets long enough not to forget that we operate in a volatile sector where fortunes can be made and lost quite rapidly. We are optimistic for the future albeit evermore cautiously not least because the current global geopolitics that can have a strong influence on shipping markets are for the time being quite opaque with too many developing situations.

2/21/2025

FIGS, Inc. holder Baron Capital discloses call option to purchase 8.79M shares at an exercise price of $6.25/sh related to Put-Call agreement ($5.27, 0.00)

  • On 19-Feb-25, pursuant to the Put-Call agreement, dated as of 7-Jan-25, by and between BAMCO, Inc., Thomas J. Tull, in his individual capacity, Thomas J. Tull in his capacity as trustee of the Tull Family Trust, u/a/d 1-Aug-05, as amended and First Light Investors, LLC, the Sellers exercised their right to require BAMCO to purchase from the Sellers, and on 20-Feb-25, BAMCO consummated the purchase of, 8.8M shares of Class A common stock at a price equal to $6.25 per share.
  • Click here to view FactSet's SharkWatch 50

2/21/2025

Neurocrine Biosciences board authorizes $500M share repurchase program ($116.11, 0.00)

  • NBIX announced that its board has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500M of its shares, subject to market conditions.
  • This new share repurchase authorization is in addition to the $300M accelerated repurchase program that was announced in October 2024 and completed in early February 2025.

2/21/2025

Vision Marine Technologiesannounces approval of stock repurchase program ($0.98, 0.00)

  • Vision Marine Technologies Inc. announced that its board has approved the establishment of a stock repurchase program authorizing the repurchase of up to 5% of Vision Marine Technologies Inc.'s outstanding common shares as of today. Company intends to enter into a 10B-18 trading plan establishing such a program.

2/21/2025

Royal Caribbean Group says it has initiated share repurchases under its recently disclosed $1B repurchase program (yesterday post-close) ($243.89, 0.00)

  • Royal Caribbean Group announced after the close yesterday that it has initiated share repurchases under the $1.0B share repurchase program disclosed last week, with $100M of shares purchased to date in open market transactions.

2/21/2025

CLEAR announces increase to its share repurchase authorization ($22.39, 0.00)

  • YOU announced that its board authorized a $200M increase to its existing Class A common stock share repurchase program, resulting in an aggregate remaining authorization of ~$232M after using ~$68M subsequent to 3Q24.

2/21/2025

NaaS Technology announces $10M share repurchase program ($1.39, 0.00)

  • The company has approved a share repurchase program, effective from 21-Feb-25
  • Pursuant to the Share Repurchase Program, the company may repurchase up to $10M of its American depositary shares over the next 12 months through the end of February 2026

2/21/2025

Vipshop Holdings reports Q4 non-GAAP net income CNY2.97B vs FactSet CNY2.67B [9 est, CNY2.46-2.83B] ($14.53, 0.00)

  • Reports Q4:
    • GAAP EPADS CNY4.69 vs year-ago CNY5.35
    • Revenue CNY33.22B vs FactSet CNY32.07B [13 est, CNY31.68-32.36B]
      • GMV CNY66.2B vs year-ago CNY66.4B
      • Number of active customers 45.7M vs year-ago 48.5M
      • Total orders 217.5M vs year-ago 234.3M
  • Board declares annual dividend of $2.40/ordinary share, or $0.48/ADS, record 11-Apr, payment 25-Apr
  • The company is committed to consistently delivering value for shareholders through both share repurchase and cash dividend in 2025
  • Q1 Guidance:
    • Revenue CNY26.3-27.6B vs FactSet CNY26.43B [1 est]